MARKET

VERA

VERA

Vera Therapeutics, Inc.
NASDAQ
50.64
-0.53
-1.04%
After Hours: 50.02 -0.62 -1.22% 18:21 12/31 EST
OPEN
51.28
PREV CLOSE
51.17
HIGH
51.28
LOW
49.95
VOLUME
1.06M
TURNOVER
--
52 WEEK HIGH
56.05
52 WEEK LOW
18.53
MARKET CAP
3.55B
P/E (TTM)
-12.7086
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VERA last week (1222-1226)?
Weekly Report · 12/29/2025 10:08
Weekly Report: what happened at VERA last week (1215-1219)?
Weekly Report · 12/22/2025 10:08
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
Reuters · 12/22/2025 07:49
VERA THERAPEUTICS INC <VERA.O>: JEFFERIES RAISES TARGET PRICE TO $60 FROM $45
Reuters · 12/22/2025 05:12
Short Report: Vera Therapeutics bears retreat as stock rallies
TipRanks · 12/21/2025 23:50
Vera Therapeutics Price Target Raised to $66.00/Share From $48.00 by B of A Securities
Dow Jones · 12/19/2025 18:02
Vera Therapeutics Is Maintained at Buy by B of A Securities
Dow Jones · 12/19/2025 18:02
B of A Securities Maintains Buy on Vera Therapeutics, Raises Price Target to $66
Benzinga · 12/19/2025 17:52
More
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

Webull offers Vera Therapeutics Inc stock information, including NASDAQ: VERA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERA stock methods without spending real money on the virtual paper trading platform.